IL‐17 is known to promote cancer progression by enhancing pro‐tumorigenic characteristics in lung cancer[55] and influencing CXC chemokine expression in breast cancer.[56] However, its precise role in the context of NKX2‐1‐low LUAD warrants further exploration. Here, IL17A is linked to breast cancer.